Literature DB >> 9578168

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.

M E Klepser1, E J Wolfe, M A Pfaller.   

Abstract

The activity of fluconazole and amphotericin B against three isolates of Cryptococcus neoformans was evaluated, with fluconazole and amphotericin B MICs of 2.0-4.0 mg/L and 1.0 mg/L respectively, using time-kill curve methods. Fluconazole was fungistatic against all isolates tested (<99.9% decrease in cfu from initial inoculum). The fungistatic activity of fluconazole was not enhanced by increasing the concentration of antifungal in solution. In contrast, amphotericin B was markedly fungicidal (> or = 99.9% decrease in cfu from initial inoculum). Both the rate and the extent of amphotericin B activity were enhanced when drug concentration was increased.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578168     DOI: 10.1093/jac/41.3.397

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

3.  Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report.

Authors:  Francesco G De Rosa; Pierpaolo Terragni; Daniela Pasero; Anna C Trompeo; Rosario Urbino; Anna Barbui; Giovanni Di Perri; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2009-06-16       Impact factor: 17.440

4.  Evaluation of voriconazole pharmacodynamics using time-kill methodology.

Authors:  M E Klepser; D Malone; R E Lewis; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii.

Authors:  Laura Rodero; Manuel Cuenca-Estrella; Susana Córdoba; Pedro Cahn; Graciela Davel; Sara Kaufman; Liliana Guelfand; Juan L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

8.  The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.

Authors:  Bing Zhai; Cheng Wu; Linqi Wang; Matthew S Sachs; Xiaorong Lin
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

9.  The Antifungal and Synergistic Effect of Bisphosphonates in Cryptococcus.

Authors:  Aidan Kane; Leona Campbell; Diana Ky; David Hibbs; Dee Carter
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

10.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.